Diabetes Screening, Risk Management and Disease Management in a High-Risk Mental Health Population Part II
1 other identifier
observational
39
1 country
1
Brief Summary
The purpose of this study is to learn more about the relationship between serious mental illness and the detection and management of diabetes and pre-diabetic conditions. Patients who have been diagnosed with schizophrenia are at an increased risk for developing diabetes and pre-diabetic conditions such as impaired glucose tolerance and impaired fasting glucose. In addition, novel antipsychotics have also been linked to impaired glucose metabolism and increased incidence of diabetes. The medical management of these patients may be difficult ot achieve through standard family practice. The objectives of this project are to: screen a sample of this high-risk population using an Oral Glucose Tolerance Test (OGTT), and to provide multidisciplinary team support to those identified as having diabetes or a pre-diabetic condition.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started May 2006
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2006
CompletedFirst Submitted
Initial submission to the registry
September 14, 2006
CompletedFirst Posted
Study publicly available on registry
September 15, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2007
CompletedNovember 6, 2018
November 1, 2018
September 14, 2006
November 2, 2018
Conditions
Interventions
Eligibility Criteria
You may qualify if:
- Patients active in current Regional Mental Health Care London, Specialized Adult London Ambulatory Care and Assertive Community Treatment programs with known diagnosis of a Psychotic Disorder and/or use of Novel Antipsychotics.
- Must have family physician contact and ability to consent to medical care.
You may not qualify if:
- Any patient with declaration on file stating incapable of consenting to medical treatment.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Regional Mental Health Care London
London, Ontario, N6A 4H1, Canada
Related Publications (3)
Crews C, Batal H, Elasy T, Casper E, Mehler PS. Primary care for those with severe and persistent mental illness. West J Med. 1998 Oct;169(4):245-50.
PMID: 9795595BACKGROUNDBrown JB, Lent B, Stirling A, Takhar J, Bishop J. Caring for seriously mentally ill patients. Qualitative study of family physicians' experiences. Can Fam Physician. 2002 May;48:915-20.
PMID: 12053636BACKGROUNDKushner K, Diamond R, Beasley JW, Mundt M, Plane MB, Robbins K. Primary care physicians' experience with mental health consultation. Psychiatr Serv. 2001 Jun;52(6):838-40. doi: 10.1176/appi.ps.52.6.838.
PMID: 11376238BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Stewart B Harris, MD MPH CCFP FACPM
Centre for Studies in Family Medicine
- PRINCIPAL INVESTIGATOR
David RS Haslam, MSc MD FRCPC
St. Joseph's Health Care London
Study Design
- Study Type
- observational
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 14, 2006
First Posted
September 15, 2006
Study Start
May 1, 2006
Study Completion
July 1, 2007
Last Updated
November 6, 2018
Record last verified: 2018-11